Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm

References

• National Institute of Mental Health. Schizophrenia. Last Revised 2016 Feb; NIH publication no. 15-3517; 2009 Avialable from: www.nimh.nih.gov/health/publications/schizophrenia-booklet/index.shtml Accessed Jul 31, 2018
   Google Scholar
• Burton N. Living with Schizophrenia. Oxford: Acheron Press; 2012:P20.
   Google Scholar
• Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–219. doi:10.1093/schbul/sbj05316481659
   PubMed Web of Science ®Google Scholar
• Blanchard JJ, Kring AM, Horan WP, et al. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37(2):291–299. doi:10.1093/schbul/sbq10420861151
   PubMed Web of Science ®Google Scholar
• Leucht S, Davis JM. Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. Lancet. 2017;389(10074):1077–1078. doi:10.1016/S0140-6736(17)30181-228185671
   PubMed Web of Science ®Google Scholar
• Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry. 2012;27(6):432–436. doi:10.1016/j.eurpsy.2011.02.01521602034
   PubMed Web of Science ®Google Scholar
• Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–1113. doi:10.1016/S0140-6736(17)30060-028185672
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management (CG178); 2014 Available from: http://www.nice.org.uk (Accessed 284 2017).
   Google Scholar
• Corponi F, Serretti A, Montgomery S, Fabbri C. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017;32(6):309–318.28727644
   PubMed Web of Science ®Google Scholar
• Jackson JH. On temporary mental disorders after epileptic paroxysms. West Riding Lunatic Asylum Med Rep. 1885;5:105‐29.
   Google Scholar
• Kraepelin E. Dementia Praecox and Paraphrenia. New York: Huntington; 1919.
   Google Scholar
• Bleuler E. Dementia Praecox, or the Group of Schizophrenias. New York: International Universities Press; 1950.
   Google Scholar
• Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam’s razor. Schizophr Bull. 2010;36(2):359–369. doi:10.1093/schbul/sbn09418644851
   PubMed Web of Science ®Google Scholar
• Malaspina D, Walsh-Messinger J, Gaebel W, et al. Negative symptoms, past and present: a historical perspective and moving to DSM-5. Eur Neuropsychopharmacol. 2014;24(5):710–724. doi:10.1016/j.euroneuro.2013.10.01824314851
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: Author; 1980.
   Google Scholar
• Schneider K. Clinical Psychopathology. New York: Grune and Stratton; 1959.
   Google Scholar
• Crow TJ. Molecular pathology of schizophrenia: more than one disease process? Bmj. 1980;280(7):66–68. doi:10.1136/bmj.280.6207.666101544
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39:789–794.7165478
   PubMed Web of Science ®Google Scholar
• Peralta V, de Leon J, Cuesta MJ. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. Br J Psychiatry. 1992;161:335–343.1356572
   PubMed Web of Science ®Google Scholar
• Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Eufest Study Group. Persistent negative symptoms in first episode patients with schizophrenia: results from the European first episode schizophrenia trial. Eur Neuropsychopharmacol. 2013;23(3):196–204. doi:10.1016/j.euroneuro.2012.04.01922647933
   PubMed Web of Science ®Google Scholar
• Carpenter WT. The deficit syndrome. Am J Psychiatry. 1994;151:327–329. doi:10.1176/ajp.151.3.3278109640
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Mucci A, Galderisi S. Primary, enduring negative symptoms: an update on research. Schizophr Bull. 2017;43(4):730–736. doi:10.1093/schbul/sbx06428575513
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: Author; 2013.
   Google Scholar
• World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
   Google Scholar
• Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3–10. doi:10.1016/j.schres.2013.05.02823800613
   PubMed Web of Science ®Google Scholar
• Davis MC, Horan WP, Marder SR. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol. 2014;24:788–799. doi:10.1016/j.euroneuro.2013.10.01024252823
   PubMed Web of Science ®Google Scholar
• Garay RP, Citrome L, Samalin L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;19:1–16.
   Google Scholar
• Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37(2):300–305. doi:10.1093/schbul/sbq05920558531
   PubMed Web of Science ®Google Scholar
• Ahmed AO, Strauss GP, Buchanan RW, Kirkpatrick B, Carpenter WT. Are negative symptoms dimensional or categorical? Detection and validation of de cit schizo-phrenia with taxometric and latent variable mixture models. Schizophr Bull. 2015;41:879–891. doi:10.1093/schbul/sbt19425399026
   PubMed Web of Science ®Google Scholar
• Barry SJ, Gaughan TM, Hunter R. Schizophrenia. BMJ Clin Evid. 2012;2012:pii: 1007.
   Google Scholar
• Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry. 2017;17:12. doi:10.1186/s12888-017-1489-628086761
   PubMed Web of Science ®Google Scholar
• Bertelsen M, Jeppesen P, Petersen L, et al. Course of illness in a sample of 265 patients with first-episode psychosis–five-year follow-up of the Danish OPUS trial. Schizophr Res. 2009;107(2–3):173–178. doi:10.1016/j.schres.2008.09.01818945593
   PubMed Web of Science ®Google Scholar
• Levine SZ, Leucht S. Attaining and sustaining remission of predominant negative symptoms. Schizophr Res. 2013;143(1):60–64. doi:10.1016/j.schres.2012.11.01023218563
   PubMed Web of Science ®Google Scholar
• Schennach-Wolff R, Jäger M, Mayr A, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients–is it all about early response? Eur Neuropsychopharmacol. 2011;21(5):370–378. doi:10.1016/j.euroneuro.2010.10.00321255982
   PubMed Web of Science ®Google Scholar
• Best MW, Grossman M, Oyewumi LK, Bowie CR. Examination of the positive and negative syndrome scale factor structure and longitudinal relationships with functioning in early psychosis. Early Interv Psychiatry. 2016;10(2):165–170. doi:10.1111/eip.1219025277757
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137(1–3):147–150. doi:10.1016/j.schres.2012.01.01522316568
   PubMed Web of Science ®Google Scholar
• Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Guastella AJ. Clinical symptoms predict concurrent social and global functioning in an early psychosis sample. Early Interv Psychiatry. 2015;12(2):177–184. doi:10.1111/eip.1229526626426
   PubMed Web of Science ®Google Scholar
• Downs J, Dean H, Lechler S, et al. Negative symptoms in early-onset psychosis and their association with antipsychotic treatment failure. Schizophr Bull. 2019;45(1):69–79. doi:10.1093/schbul/sbx19729370404
   PubMed Web of Science ®Google Scholar
• Ventura J, Subotnik KL, Gitlin MJ, et al. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res. 2015;161(2–3):407–413. doi:10.1016/j.schres.2014.10.04325499044
   PubMed Web of Science ®Google Scholar
• Hovington CL, Bodnar M, Joober R, Malla AK, Lepage M. Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms. Schizophr Res. 2013;147(2–3):223–229. doi:10.1016/j.schres.2013.04.00623628602
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578–583. doi:10.1176/ajp.145.5.5783358462
   PubMed Web of Science ®Google Scholar
• Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19(Suppl 1):38–52. quiz 35-7, 53 DOI:10.1017/S109285291400060125403863
   PubMed Web of Science ®Google Scholar
• Galderisi S, Quarantelli M, Volpe U, et al. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull. 2008;34(2):393–401. doi:10.1093/schbul/sbm09717728266
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Progress in the study of negative symptoms. Schizophr Bull. 2014;Suppl 2:S101–S106. doi:10.1093/schbul/sbt15824562490
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry. 2008;7:143–147. doi:10.1002/wps.2008.7.issue-318836581
   PubMed Web of Science ®Google Scholar
• Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33:1013–1022. doi:10.1093/schbul/sbl05717099070
   PubMed Web of Science ®Google Scholar
• Galderisi S, Maj M, Mucci A, et al. Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry. 2002;159(6):983–990. doi:10.1176/appi.ajp.159.6.98312042187
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.3616518
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36–45. doi:10.1097/JCP.0b013e31823f880a22198451
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Song G, Kinon BJ, et al. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr Res. 2012;134:195–201. doi:10.1016/j.schres.2011.09.02822019076
   PubMed Web of Science ®Google Scholar
• Alphs L, Panagides J, Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale. Psychopharmacol Bull. 2007;40:41–53.
   PubMed Web of Science ®Google Scholar
• Marder SR, Alphs L, Anghelescu I-G, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res. 2013;150(2–3):328–333. doi:10.1016/j.schres.2013.07.05824028744
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625–639. doi:10.1007/s00406-018-0869-329368205
   PubMed Web of Science ®Google Scholar
• Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011;72:4–8. doi:10.4088/JCP.10075su1.0122217436
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777. doi:10.2147/TCRM.S11732128721057
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. doi:10.1016/S0140-6736(08)61764-X19058842
   PubMed Web of Science ®Google Scholar
• Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2004;7(1):S15–S20. doi:10.1017/S146114570400410914972080
   PubMed Web of Science ®Google Scholar
• Kumar S, Chaudhury S. Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: an open-label clinical study. Ind Psychiatry J. 2014;23(1):27–35. doi:10.4103/0972-6748.14495325535442
   PubMedGoogle Scholar
• Levine SZ, Leucht S. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophr Res. 2014;156(1):107–114. doi:10.1016/j.schres.2014.04.00524794879
   PubMed Web of Science ®Google Scholar
• Möller HJ. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2001;251(5):217–224.11829208
   PubMed Web of Science ®Google Scholar
• Pani L, Gessa G. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry. 2002;7:247–253. doi:10.1038/sj.mp.400104011920152
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat. 2018;14:2563–2577. doi:10.2147/NDT.S15970430323605
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193–206. doi:10.1517/17425255.2013.75921123320989
   PubMed Web of Science ®Google Scholar
• Németh B, Molnár A, Akehurst R, et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017;6(8):639–648. doi:10.2217/cer-2017-002428511548
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Khan A, Iskander A, et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007;68(3):368–379. doi:10.4088/JCP.v68n030317388705
   PubMed Web of Science ®Google Scholar
• Riedel M, Muller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005;255(6):432–437. doi:10.1007/s00406-005-0622-616267634
   PubMed Web of Science ®Google Scholar
• Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry. 1992;31:698–704. doi:10.1016/0006-3223(92)90279-91599987
   PubMed Web of Science ®Google Scholar
• Spina E, De Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol. 1994;9:281–285. doi:10.1097/00004850-199400940-000077868850
   PubMed Web of Science ®Google Scholar
• Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology. 1995;117:417–423. doi:10.1007/BF022462137604142
   PubMed Web of Science ®Google Scholar
• Salokangas RK, Saarijärvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1996;94:175–180. doi:10.1111/j.1600-0447.1996.tb09844.x8891083
   PubMed Web of Science ®Google Scholar
• Taiminen TJ, Syvälahti E, Saarijärvi S, et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol. 1997;12:31–35. doi:10.1097/00004850-199701000-000049179631
   PubMed Web of Science ®Google Scholar
• Jockers-Scherübl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics. Int Clin Psychopharmacol. 2005;20:27–31. doi:10.1097/00004850-200501000-0000615602113
   PubMed Web of Science ®Google Scholar
• Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(9):876–886. doi:10.1176/appi.ajp.2016.1508103527282362
   PubMed Web of Science ®Google Scholar
• Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005;80(1):85–97. doi:10.1016/j.schres.2005.07.03516183258
   PubMed Web of Science ®Google Scholar
• Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197(3):174–179. doi:10.1192/bjp.bp.109.06771020807960
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892–899. doi:10.1093/schbul/sbu17025528757
   PubMed Web of Science ®Google Scholar
• Cariprazine Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/reagila-epar-product-information_en.pdf. Accessed May 20, 2019.
   Google Scholar
• Carlsson A, Carlsson ML. A dopaminergic deficit hypoth- esis of schizophrenia: the path to discovery. Dialogues Clin Neurosci. 2006;8:137–142.16640125
   PubMedGoogle Scholar
• Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188:1217–1219. doi:10.1126/science.11451941145194
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/S0140-6736(13)60733-323810019
   PubMed Web of Science ®Google Scholar
• Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clin Psychol Rev. 2013;33(8):914–928. doi:10.1016/j.cpr.2013.07.00123988452
   PubMed Web of Science ®Google Scholar
• Peters JU. Polypharmacology—foe or friend? J Med Chem. 2013;56:8955–8971.23919353
   PubMed Web of Science ®Google Scholar